---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-021195"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2025-11-07T23:59:59+00:00"
generated_at: "2026-05-16T23:09:06.032555+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "medium"
source: SEC EDGAR
---

# MAIA Biotechnology presents THIO-104 and THIO-101 posters at SITC 2025 for NSCLC trials

## Summary
- THIO-104 Phase 3 study of ategano sine (THIO) sequenced with ICI vs SOC chemo in ICI-resistant advanced NSCLC presented Nov 7.
- THIO-101 Phase 2 study of THIO combined with ICI in advanced NSCLC resistant to prior ICI and chemo presented Nov 10.
- Posters are in-progress trial updates and contain forward-looking statements; detailed results not disclosed in the filing.

## SEC filing metadata
- accession: 0001493152-25-021195
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2025-11-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000149315225021195/0001493152-25-021195-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000149315225021195/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-021195
- JSON: https://secwatch.observer/filing/0001493152-25-021195.json
- Plain text: https://secwatch.observer/filing/0001493152-25-021195.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.